Sonidegib

(Odomzo®)

Sonidegib

Drug updated on 11/10/2023

Dosage FormCapsule (oral; 200 mg)
Drug ClassHedgehog pathway inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Odomzo (sonidegib) Prescribing Information.2019Sun Pharmaceutical Industries, Inc., Cranbury, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines